Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 24, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - March 24, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/17/17 - "Dosing Preparation of Dabigatran Etexilate Or a Salt Thereof and a Preparation Method Thereof" in Patent Application Approval Process (USPTO...
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors SHENG, Xiaoxia; TANG, Yong, filed on October 8, 2015, was made available online on March 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to SoliPharma LLC. Dabigatran etexila
3/17/17 - "Pharmaceutical Composition and Method for Treatment and Prevent of Hair Loss." in Patent Application Approval Process (USPTO 20170049675)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Momplaisir, Thierry, filed on August 4, 2016, was made available online on March 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institution. The fol
3/17/17 - 5 Biotech Companies Set for Major Breakouts in 2017
There's nothing more potentially rewarding right now than a visionary biotech company, poised for explosive gains, on the basis of a ground-breaking drug, medical device or procedure. Biotechs worth a look in the markets, include: Cara Therapeutics, Inc., Clovis Oncology, Inc., Biogen Inc., Celgene Corporation, Mylan N.V. amongst others. Amgen is t
3/17/17 - 5 Biotech Companies To Watch In 2017
There "s nothing more potentially rewarding right now than a visionary biotech company poised for explosive gains on the basis of a ground-breaking drug, medical device or procedure. Large-cap or small-cap, this is the definitive year of biotech, and these five picks are all set for big things in 2017- with momentous catalysts that promise massive
3/17/17 - AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April
AcelRx Pharmaceuticals, Inc.,, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Senior Management will be presenting at the Oppenheimer's 27th Annual Healthcare Conference, The MicroCap Conference, and the CF&B...
3/17/17 - Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed Products
Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC today announced that they have entered into a License Agreement to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada. MainPointe is an emerging OTC pharmaceutical company that brings added leverage to our NEXAFED business, commented Bob Jones, Ac
3/17/17 - Aeolus Pharmaceuticals, Inc. to Present at The MicroCap Conference on April 4th in New York City at the Essex House
NEW YORK, NY/ ACCESSWIRE/ March 17, 2017/ Aeolus Pharmaceuticals, Inc., a clinical stage biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage, and infection, will be presenting at this year's The MicroCap Conference on April 4th in New York City, sponsored by The Special Equities Group and Maxim Group.
3/17/17 - Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference [National Iraqi News Agency (Iraq)]
-Agile Therapeutics, Inc., a womens healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla,, also known as AG200-15. The poster, titled The SECURE Study, a Real-World Trial of a Low-Dose Contraceptive Patch: Addressing the Changing U.S. Population, will be presented
3/17/17 - Akari Therapeutics Announces R&D Day on April 24, 2017
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research and Development Day on April 24, 2017 in New York. Interim results from the ongoing phase 2 trial in paroxysmal nocturnal hemoglobinuria will be presented by Dr Anita Hill, the lead investigator in the study. Dr Hill is a
3/17/17 - Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 37th Annual Health Care Conference
By a News Reporter-Staff News Editor at Drug Week Alkermes plc announced that its corporate presentation will be webcast live at the Cowen and Company 37th Annual Health Care Conference on Tuesday, Mar. 7, 2017 at 8:00 a.m. ET from The Boston Marriott Copley Place in Boston. Alkermes plc is a fully integrated, global biopharmaceutical company dev
3/17/17 - Allergan to Present at the Barclays Global Healthcare Conference
By a News Reporter-Staff News Editor at Drug Week Allergan plc, a leading global biopharmaceutical company, announced that Chairman and CEO Brent Saunders will present at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will be webcast live and can be accessed on Allergan's Investor Relations website at HYPERLINK "...
3/17/17 - Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)
Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that interim Phase 1 trial results from autologous, targeted Epstein-Barr Virus Specific Cytotoxic T Lymphocytes, or the autologous...
3/17/17 - Benitec Biopharma Ltd Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16] (Feb. 23, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Benitec Biopharma Ltd was posted on February 23, 2017. The SEC file number is 0001144204-17-010491.. A U.S. Securities and Exchange Commission filing is a forma
3/17/17 - BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
BioDelivery Sciences International, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2016, and provided an update on recent business highlights and upcoming milestones. The transfer of worldwide rights back to BDSI followed a strategic decision announced by Endo in December 2016 to discontinue commerci
3/17/17 - BioQ Pharma to Present at 27th Annual Oppenheimer Healthcare Conference
BioQ Pharma Incorporated, a specialty pharmaceutical company, announced today that the Company will be presenting at the 27th Annual Oppenheimer Healthcare Conference to be held in New York City on March 21st and 22nd, 2017.. Josh Kriesel, President and Chief Executive Officer, is scheduled to present on Wednesday, March 22nd at 2:45 p.m. Eastern
3/17/17 - Blog Coverage PTC Therapeutics Acquires Rights for Duchenne Muscular Dystrophy Drug from Marathon for $140 Million Upfront
LONDON, UK/ ACCESSWIRE/ March 17, 2017/ Active Wall St. blog coverage looks at the headline from PTC Therapeutics, Inc. as the Company announced on March 16, 2017, that it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza? for $140 million upfront. One of PTC Therapeutics' competitors
3/17/17 - Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation
In this U.S. Medicare database analysis, Eliquis was associated with significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin. PRINCETON, N.J.& NEW YORK Bristol-Myers Squibb Company and Pfizer Inc. today announced findings from a real-world data analysis of the U.S. Medicare database compa
3/17/17 - Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants...
Bristol-Myers Squibb Company and Pfizer Inc. today announced findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin. In the analysis, title
3/17/17 - Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16] (Feb. 28, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Can-fite Biopharma Ltd. was posted on February 28, 2017. The SEC file number is 0001213900-17-001821.. A U.S. Securities and Exchange Commission filing is a for
3/17/17 - Cholesterol drug cuts heart risks, spurs new debate on cost
A long-acting cholesterol medicine cut the risk of having a heart attack or some other serious problems by 15 to 20 percent in a big study that's likely to spur fresh debate about what drugs should cost. It costs more than $14,000 a year, and insurers have balked at paying without proof that it lowers heart risks, not just the cholesterol number.
3/17/17 - CorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
BEDMINSTER, NJ/ ACCESSWIRE/ March 17, 2017/ CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided its corporate update for the fourth quarter and full year ended December 31, 2016. CorMedix will host a conferen
3/17/17 - CTD HOLDINGS INC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
We filed a Type II Drug Master File with the FDA in 2014 for our lead drug candidate, Trappsol Cyclo? as a treatment for Neimann-Pick Type C disease, a rare and fatal cholesterol metabolism disease found primarily in children and young adults. In 2016, we filed an Investigational New Drug application with the FDA, which describes our Phase I c
3/17/17 - Cti Biopharma Corp. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Feb. 27, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on February 27, 2017. The SEC file number is 0000899243-17-005429.. A U.S. Securities and Exchange Commission filing is a formal
3/17/17 - Cti Biopharma Corp. Files SEC Form 8-K, Current Report (Feb. 27, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on February 27, 2017. The SEC file number is 0000891293-17-000023.. A U.S. Securities and Exchange Commission filing is a formal
3/17/17 - CURE Pharmaceutical To Exhibit at INTERPHEX 2017 in New York City [Syrian Arab News Agency]
-CURE Pharmaceutical, or, a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, nutraceutical and medical foods markets, and developing cannabinoid molecules and new chemical entities, today announces it will be an exhibitor at the INTERPHEX 2017 conference on March 21-23 at the Javits Center, 655
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415